TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04731909
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.
Study: NCT04731909
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2,d1,q3w,4-6 cycles in total.
Study: NCT04731909
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=5,d1,q3w,4-6 cycles in total.
Study: NCT02408432
Drug: Mesenchymal Stem Cell Transplantation
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo mesenchymal stem cell infusion
Study: NCT00637143
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00637143
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00000187
Drug: Ritanserin
Normalized name: RITANSERIN
DrugBank: Ritanserin (DB12693)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03576547
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT03576547
Drug: Ponatinib Hydrochloride
Normalized name: Ponatinib Hydrochloride
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03576547
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00413088
Drug: bemiparin
Normalized name: Bemiparin
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03079869
Drug: Ferric Citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
Study: NCT03539536
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT03976076
Drug: JBPOS0101
Normalized name: JBPOS0101
DrugBank: JBPOS0101 (DB16034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JBPOS0101 (investigational product)
Study: NCT00792142
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00792142
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00792142
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00792142
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00850382
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse).
Study: NCT00850382
Drug: daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3
Study: NCT00850382
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (\>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours.
Study: NCT00163371
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04188860
Drug: A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for all patients:~* Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months~* Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
Study: NCT00075465
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00075465
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00445458
Drug: HKI-272
Normalized name: HKI-357
DrugBank: HKI-357 (DB13002)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00445458
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00004009
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01012648
Drug: Fluid resuscitation
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume resuscitation
Study: NCT00401180
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
Study: NCT00401180
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
Study: NCT02331095
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP).
Study: NCT04384731
Drug: poractant alfa
Normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient receiving surfactant (3 mL/kg of a poractant alpha solution diluted to 16 mg/mL, resulting in a total dose of 48mg/kg) administred by bronchial fibroscopy. The total volume will be divided in each of the five lobar bronchi.
Study: NCT02483260
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Loading dose, 33 mg/kg (maximum dose: 2.64 g)~2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses).
Study: NCT02554344
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
Study: NCT04469829
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard doses of secukinumab for psoriasis
Study: NCT02024152
Drug: JDP-205 IV high dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00720304
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
Study: NCT00720304
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
Study: NCT02024152
Drug: JDP-205 IV low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04418401
Drug: Donafenib and anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
Study: NCT02360059
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
Study: NCT00698607
Drug: 6-month clopidogrel therapy
Normalized name: varenicline
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Use clopidogrel for 6 months
Study: NCT00698607
Drug: 12-month clopidogrel therapy
Normalized name: varenicline
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Use clopidogrel for 12 months
Study: NCT00744354
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
Study: NCT00744354
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
Study: NCT00764244
Drug: Intravitreal triamcinolone injections
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal triamcinolone injections
Study: NCT02244086
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
Study: NCT00996918
Drug: Bapineuzumab 1.0 m/kg
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Study: NCT01339000
Drug: Glycosylated Recombinant Human Interleukin-7
Normalized name: Glycosylated recombinant human interleukin-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection
Study: NCT02341209
Drug: Doxycycline monohydrate
Normalized name: Doxycycline Monohydrate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
Study: NCT00728988
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
Study: NCT00728988
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg daily after PCI for 30 days.
Study: NCT00958997
Drug: 18F-FP-DTBZ (18F-AV-133)
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
Study: NCT00799773
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
Study: NCT03273712
Drug: Amino Acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
Study: NCT03758885
Drug: Nolasiban
Normalized name: Nolasiban
DrugBank: Nolasiban (DB16259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nolasiban single oral administration
Study: NCT02302430
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 International Units Intranasal Oxytocin
Study: NCT02359175
Drug: Bupivacaine in epidural catheter
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacain to be given in epidural catheter
Study: NCT02359175
Drug: Placebo (for Bupivacain and Fentanyl i epidural catheter)
Normalized name: BUPIVACAINE/FENTANYL
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline to be given in epidural catheter
Study: NCT02736409
Drug: Oral Budesonide Suspension (OBS)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: OBS 2mg twice daily
Study: NCT03467360
Drug: acetazolamide in combination with platinum and etoposide-based radiochemotherapy
Normalized name: platinum
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
Study: NCT03467360
Drug: acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
Study: NCT03768388
Drug: levoketoconazole
Normalized name: LEVOKETOCONAZOLE
DrugBank: Levoketoconazole (DB05667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: food effect
Study: NCT00530088
Drug: porfimer sodium
Normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT04335201
Drug: Defibrotide Injection
Normalized name: defibrotide Injection
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
Study: NCT02777749
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
Study: NCT03253471
Drug: AL-611
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-611 tablets
Study: NCT04485065
Drug: IBI188+azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Escalating and maintenance dose of IBI188 will be administered 30mg/kg, IV(intravenous infusion),Q4W~Drug:Azacitidine Azacitidine will be administered daily for 7 days, IH, Q4W
Study: NCT02725489
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
Study: NCT00416897
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02804191
Drug: LO2A
Normalized name: Levonorgestrel and Ethinyl Estradiol
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: eye drop solution.
Study: NCT02804191
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT02720094
Drug: Cabotegravir Oral Tablet
Normalized name: cabotegravir Oral Tablet
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg tablet
Study: NCT02720094
Drug: Placebo for cabotegravir oral tablet
Normalized name: cabotegravir Oral Tablet
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02720094
Drug: CAB LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
Study: NCT04699721
Drug: nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
Study: NCT04234516
Drug: Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
Study: NCT04234516
Drug: Morphine Sulfate 30 mg
Normalized name: morphine sulfate 30 MG
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
Study: NCT01268579
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
Study: NCT04445389
Drug: GX-19
Normalized name: GX-19 Vaccine
DrugBank: GX-19 Vaccine (DB15891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen
Study: NCT04445389
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline
Study: NCT02324543
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV on days 4 and 11 of a 21 day cycle
Study: NCT02324543
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV on days 4 and 11 of a 21 day cycle
Study: NCT02324543
Drug: Xeloda
Normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twice a day orally on days 1 through 14 of a 21 day cycle
Study: NCT02649959
Drug: CM-AT
Normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single unit does powder of active substance (CM-AT) administered 3 times per day
Study: NCT02324543
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV on days 4 and 11 of a 21 day cycle
Study: NCT02324543
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV on days 4 and 11 of a 21 day cycle
Study: NCT01548144
Drug: Crizotinib (Xalkori)
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1.
Study: NCT01548144
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.
Study: NCT01548144
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1.
Study: NCT03108781
Drug: Lavender Oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender Oil twice a day; one month on the face and one month on the legs
Study: NCT03108781
Drug: sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice a day (sunflower oil); one month on the face and on month on the legs
Study: NCT00282464
Drug: Geodon (Ziprasidone)
Normalized name: ziprasidone Injection [Geodon]
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
Study: NCT00612898
Drug: apricitabine
Normalized name: Apricitabine
DrugBank: Apricitabine (DB12855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg BID apricitabine orally for 48 weeks
Study: NCT00612898
Drug: lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150mg BID lamivudine orally for 48 weeks
Study: NCT03748043
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
Study: NCT02202356
Drug: ALS-008176
Normalized name: ALS-008176
DrugBank: Lumicitabine (DB14808)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01345058
Drug: lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide maximum of 200 mg/day, to be titrated as follows:~* Week 1: 50 mg twice a day~* Beginning Week 2: 100 mg twice a day.